Cyclin D1 is a weak oncogene that cooperates with c-myc activation in the development of B cell lymphomas in transgenic animals. Cyclin D1 is constantly overexpressed in human mantle cell lymphomas (MCL). However, the status of c-myc gene in these tumors is not known. We have examined the cmyc mRNA expression and genomic alterations, including mutational analysis of exon 1, intron 1, and exon 2 regulatory elements, in a series of 33 MCL, 22 typical and 11 blastoid variants. In addition, c-myc alterations were also examined in 56 nodal non-Hodgkin's lymphomas (NHL). c-myc mRNA overexpression was found in 38% (11/29) of MCL with a slightly higher frequency in blastoid variants (5/10, 50%) than in typical cases (6/19, 31%). Genetic alterations were only found in one blastoid MCL showing a three-fold c-myc gene amplification. In other nodal NHL, c-myc overexpression was found in 24% (7/29) of indolent tumors but in 70% (19/27) of aggressive variants. c-myc Genetic alterations detected in these cases were gene rearrangement and hypermutations in one Burkitt's lymphoma, and individual point mutations in intron 1 or exon 2 in 1/19 (5%) indolent and 7/16 (44%) aggressive variants. These results indicate that c-myc is overexpressed in a subset of MCL, but structural gene alterations are less frequent than in other nodal NHL.
Introduction
Mantle cell lymphoma (MCL) is a lymphoproliferative disorder genetically characterized by translocations of the 11q13 region and its molecular counterpart bcl-1 rearrangements. 1, 2 This genetic alteration plays a major role in the pathogenesis of these lymphomas by deregulating the expression of cyclin D1 gene. Cyclin D1 participates in the control of the G1 phase of the cell cycle by binding to the cyclin-dependent kinases (CDK) 4 and 6. 3 The complexes between these kinases, particularly CDK4, and cyclin D1 phosphorylate retinoblastoma and related proteins such as p107 leading to the inactivation of their suppressor effect on the cell cycle progression. 4 Transfection and transgenic animal studies have also indicated that cyclin D1 may function as an oncogene but needs to cooperate with other oncogenes in cellular transformation. [5] [6] [7] Particularly, transgenic mice overexpressing cyclin D1 only develop mammary hyperplasias. 8 In addition, ectopic expression of cyclin D1 in lymphoid cells does not predispose the animals to develop lymphoid neoplasms. However, double transgenic mice overexpressing cyclin D1 and c-myc have a rapid development of B cell lymphomas suggesting a strong cooperative effect between c-myc and cyclin D1 genes in lymphomagenesis. 5, 7 These findings in experimental animals suggest that c-myc may also cooperate with cyclin D1 in the development of human MCLs. However, the status of c-myc expression and gene configuration in these tumors is not known.
The c-myc proto-oncogene is a transcription factor that acts in conjunction with its partner Max in the regulation of genes implicated in normal cell proliferation and apoptosis. 9 Overexpression of this gene and genetic alterations including amplifications or rearrangements are known mechanisms of c-myc oncogenic activation in the pathogenesis of several neoplasms including human non-Hodgkin's lymphomas (NHLs). 10 In addition, mutations in regulatory regions are frequently associated with the rearrangement of the gene and seem to participate in the oncogenic activation of the protein.
These regulatory areas are mainly located in the exon 1/intron 1 boundary and include elements for the control of transcription elongation, splicing sites, and alternative promoter initiation. 10 Intron 1 also contains three binding sites for myc intron factors (MIF 1-3) that seem to act as negative transcriptional regulatory elements. 11 Finally, mutations in exon 2 tend to cluster in regions associated with phosphorylation and transactivation and seem to participate in the oncogenic potential of the gene. 12, 13 Genetic alterations in these regions have been well characterized in different types of lymphomas including Burkitt's lymphoma, AIDS-associated lymphoma, anaplastic large cell lymphoma, MALT lymphoma, and other NHLs. [13] [14] [15] [16] [17] However, the status of c-myc gene in MCLs has not been previously examined.
Thus, to determine the potential role of c-myc alterations in the pathogenesis of MCLs, we have examined the mRNA expression and the configuration of the gene, including the analysis of exon 1, intron 1 and exon 2 regulatory elements, in a series of typical and blastoid variants of these tumors. In addition, c-myc alterations were also examined in a group of other nodal NHLs.
Materials and methods

Patients and tissues
Tumor specimens from 33 MCLs were selected from the files of the Hematopathology Section of the Hospital Clinic of Barcelona based on the availability of frozen tissue for molecular analysis. A total of 22 cases were classified as typical MCLs and 11 as blastoid variants according to previously described criteria. 18 All these cases had been examined for cyclin D1 expression by Northern blot analysis and for immunohistochemistry, and it was overexpressed in all the cases. In addition, 56 nodal non-Hodgkin's lymphomas were also examined. These cases were diagnosed following previously described criteria 19 and included 14 chronic lymphocytic leukemias (CLL), three hairy cell leukemias, 12 follicular lymphomas, 13 de novo large cell lymphomas, four large cell lymphomas evolved from follicular lymphomas, six large cell lymphomas progressed from CLL (Richter's syndrome), two Burkitt's lym-phomas, one lymphoblastic lymphoma and one anaplastic large cell lymphoma. Finally, eight samples of non-neoplastic lymphoid tissues, including three reactive lymph nodes, three tonsils and two spleens, and three hematological cancer cell lines (Molt-4, K562 and Raji) were also examined. The cell lines were purchased from the American Type Culture Collection, Rockville, MD, USA and grown in Rosewell Park Memorial Institute medium (RPMI, Gibco, Paisley, UK) containing 15% fetal calf serum in a 5% CO 2 humidified atmosphere.
RNA extraction and Northern blot analysis
Total RNA was isolated in 85 cases, 29 MCL and 56 nodal NHL, from frozen tissues using guanidine isothiocyanate extraction and cesium chloride gradient centrifugation as described previously. 20 Fifteen micrograms of total RNA were electrophoresed on a denaturing 1.2% agarose formaldehyde gel and transferred to Hybond-N membranes (Amersham, Buckinghamshire, UK). The membranes were prehybridized, hybridized with the c-myc probe, and washed as described previously. 21 The probe was radiolabeled using a random primer DNA labeling kit (Promega, Madison, WI, USA) with ␣-
32
P dCTP. The c-myc probe was a 1.4-kb ClaI/EcoRI fragment containing the third coding exon and was provided by R Dalla Favera, Columbia University, New York. In each blot, total RNA from Molt-4 and K562 cell lines was also included as positive and negative control, respectively. The presence of these cell lines in all the blots allowed inter-blot comparison of the signals. Hybridization signals of different radioautographic exposures were quantified using a UVP-GDS5000 video densitometer (UVP, San Gabriel, CA, USA). The hybridization signal of each case was normalized to the respective 28S RNA band for loading differences and to the signal of the Molt-4 cell line present in all blots to standardize the signals between blots. Expression was then presented as relative units related to the expression of the control case. Overexpression was considered when the mRNA levels of the tumor were more than 0.5 relative units. This cut-off represented two-fold the mean c-myc expression levels detected in non-neoplastic lymphoid tissues included in the study. Moderate c-myc expression was considered between 0.5 and 0.3 relative units. Lower values were considered as negatives.
DNA extraction and Southern blot analysis
Genomic DNA was extracted from frozen samples of 65 cases, 29 MCL and 36 non-Hodgkin's lymphomas, including four cases without available mRNA. DNA was obtained using Proteinase K/RNAse treatment and phenol-chloroform extraction, and 15 g were digested with EcoRI and HindIII, separated on 0.8% agarose gels, and transferred to Hybond-N membranes (Amersham). The membranes were prephybridized and hybridized with the c-myc as previously described. 21 To normalize the loading, the blots were hybridized with ␤-actin probes, after stripping off the c-myc probe. Intensities of c-myc bands were normalized to ␤-actin control. The signals of the Southern blot analysis were quantified with the same system used in the Northern blot analysis.
SSCP analysis
The same series of 65 NHLs examined by Southern blot were also analyzed for the presence of c-myc gene mutations in the regulatory regions of exon 1/intron 1 boundary, intron 1 and exon 2, using SSCP-PCR of genomic DNA, according to a modified protocol of a previously described method. 22 The exonl/intronl boundary of the c-myc gene was investigated using the pair of oligonucleotides: MIA, 5Ј-CAT-TTGCACTGGAACTTACA-3Ј and MIB, 5Ј-CAGGAATGGGA-GAAAAGACAC-3Ј. The c-myc regions located in intron 1 named myc intron factor 1-3 (MIF 1-3) were studied with: M2A, 5Ј-GCTGAGATGAGTCGAATGCC-3Ј and M2B, 5Ј-AAGGAGCTCAGGATGCAAGG-3Ј. The primers used for exon 2 mutational analysis were previously used in other studies. 13, 16 Amplifications were performed with 0.1 g of genomic DNA, 2.5 U of Taq polymerase (Boehringer Mannheim, Mannheim, Germany), 0.5 mol/l of each primer, 100 mol/l of dNTPs and PCR buffer in a final volume of 50 l. PCR conditions were one step at 95°C for 5 min, 35 cycles at 95°C for 1 min, 65°C for 1 min and 72°C for 1 min. The reactions were performed in a Perkin Elmer 480 thermocycler (Norwalk, CT, USA). PCR products of all the amplifications were diluted 10-fold in formamide-dye loading buffer, incubated for 3 min at 95°C, and immediately cooled on ice. Twenty microliters were loaded on a non-denaturing 15% polyacrylamide gel or in 8% polyacrylamide gel containing 7% glycerol. The two types of gel were electrophoresed at 80 V and 120 V respectively. for 19 h at room temperature. The gels were developed using a previously described silver staining procedure. 23 One case of Burkitt's lymphoma and the derived cell line Raji were incorporated in the SSCP analysis as positive controls. 13 
DNA sequencing
PCR products with altered migration were reamplified in a second independent PCR, purified and sequenced using a commercial cycle sequencing kit (Amplicycle; Perkin Elmer) and ␣-33 P dATP. The reaction was performed according to the instructions supplied by the manufacturer. The conditions of the amplification reaction of all the fragments were 30 cycles at 94°C for 1 min, 65°C for 1 min and 72°C for 1 min 30 s using the primers mentioned above. The final volume was diluted two-fold in formamide-dye loading buffer. Samples were denatured for 3 min at 95°C and 2 l were analyzed in a denaturing 6% polyacrylamide/8M urea sequencing gel for 2 or 3 h at 55 W. The gels were dried under vacuum at 85°C and exposed to an X-ray film at room temperature for 3 days without intensifying screen. The presence of a mutation was confirmed by sequencing the other DNA strand.
Ki-67 immunohistochemical study
The proliferation rate of MCLs was analyzed in formalin-fixed paraffin-embedded sections using the anti Ki-67 monoclonal antibody MIB-1 (Immunotech, Marseille, France) which recognizes a fixation-resistant epitope of this molecule. 24 Before the application of the primary antibody, an antigen retrieval technique was performed. The deparaffinized and rehydrated slides were placed in 10 mmol/l citrate buffer (pH 6), and heated in a microwave oven for 15 min at 700 W. 24 The MIB monoclonal antibody was incubated at 2 g/ml, overnight at 4°C. The antibody was detected by means of the streptavidin-biotin-alkaline phosphatase (Biogenex, San Ramon, CA, USA) technique using Fast-Red as chromogen. Levamisole was used to inhibit endogenous alkaline phospha- tase. The slides were counterstained with hematoxylin. Sections from hyperplastic tonsils were used as positive controls.
Quantitative immunohistochemical analysis was performed using a computerized digital analyzer (MicrocomImage Processing IMCO; Kontron Electronik, Munich, Germany) to score the nuclei of the tumor cells for the presence of Ki-67 protein. The value measured was the percentage of the immunohistochemically stained area against that of the total nuclear area. Nuclear boundary optical density and antibody threshold were adjusted for each case examined. Five or more fields of each tumor were analyzed until a minimum of 1000 cells had been examined. The fields were selected in each slide from the areas with the greatest number of stained cells.
Statistical analysis
Differences among the histologic variants as well as the other initial variables (clinical data, hematological and biochemical parameters) in terms of c-myc overexpresion were compared by the Fisher's exact test (two-tailed). This test was also used for comparison of Ki-67 positivity and c-myc overexpressed MCLs, using a different cut-off point for Ki-67 positivity and a linear regression analysis (Pearson product-moment correlation) to test a quantitatively possible association between these two parameters. The actual survival analysis was performed according to the method described 25 and the curves were compared by the log rank test. 26 Non-parametric tests (Mann-Whitney) were used when necessary.
Results
c-myc mRNA expression
c-myc mRNA expression was examined in 29 MCLs, 19 typical and 10 blastoid variants. The expression levels were variable from case to case with values ranging from negligible to 2.5 relative units. Overexpression (Ͼ0.5 relative units) was more frequently observed in the blastoid variants (50%) than in typical forms (31%), but this difference did not reach statistical significance (P = 0.43) (Figure 1, Table 1) . To determine the possible correlation between c-myc mRNA levels and the proliferative activity of these tumors, Ki-67 expression was examined by immunohistochemistry and analyzed by computerized image analysis. 27 No correlation between c-myc expression and proliferative activity of the tumors was found. Similarly, no correlation was found between the c-myc expression levels of the tumors and cyclin D1 mRNA expression, the main clinical characteristics, response to treatment, or the overall and disease-free survival of the patients.
c-myc expression was also examined in 56 additional nodal NHLs. Similarly to typical and blastoid MCLs, c-myc overexpression was detected in 28% CLLs and 25% follicular lymphomas, but in 54% de novo large cell lymphomas, 83% large cell lymphomas evolved from CLL, 100% transformed follicular lymphomas, and in the Burkitt's and lymphoblastic lymphomas examined (Table 2 ). All tumors taken together, c-myc overexpression was significantly more frequent in aggressive (65%) than in indolent lymphomas (27%) (P Ͻ 0.001, twotailed exact Fisher test). 
Southern blot analysis
Southern blot analysis could be performed in 29 MCLs. No rearrangements were detected in any case and only one blastoid MCL showed a three-fold c-myc gene amplification ( Figure 2 , Table 1 ). No RNA was available in this case to determine expression levels. c-myc gene was also examined by Southern blot in 36 additional NHLs including 13 cases with c-myc mRNA overexpression. No c-myc gene amplifications or rearrangements were detected in any case, with the exception of a rearrangement observed in the Burkitt's lymphoma which is included in the study.
SSCP and sequencing analysis
SSCP and sequencing analysis was performed in the same series of tumors using several PCR amplifications spanning exon 1/intron 1 boundary, the whole intron 1 including MIF regions (MIF1-3), and exon 2. In MCLs, only four typical cases showed a common altered SSCP mobility in exon 2 ( Figure  3 ). Sequencing analysis of these cases showed that this alteration was due to a previously described polymorphism in Asn 11 (Asn → Ser) 28 ( Table 2 ). The frequency of this polymorphism in MCLs (14%) was similar to that previously observed in a normal population (13%). 28 In the additional nodal NHLs, we detected intron 1 altered SSCP mobility in six de novo large cell lymphomas and one Richter's syndrome. Sequencing analysis showed different mutations spanning intronic positions 2886 to 3082 ( Table 2) . One of these mutations in a LCL was located in the regulatory MIF-1 box and a second one, corresponding to a c-myc overexpressing Richter's syndrome, was located very near the exon1/intron1 splicing site. The rest of intron 1 mutations were located in other positions relatively far from the MIF regions and the exonl/intron 1 boundary (Table 2) . c-myc mRNA overexpression was observed in all these cases with gene mutations with the only exception a LCL with a mutation at position 170 of the intron 5Ј end. To confirm that these intronic mutations were not polymorphisms, an SSCP analysis of DNA from normal tissues could be performed in five of these cases. A germ line configuration of the gene was observed in all normal samples suggesting that the mutations were associated with the malignant transformation of the cells. c-myc exon 2 analysis showed a missense mutation in codon 59 (C-ϾG; Pro-ϾAla) in a follicular lymphoma ( Figure  4 , Table 2 ). This case was a grade 3 (large cell type) follicular lymphoma with a bulky abdominal mass, generalized lymphadenopathy, and high LDH serum levels (1177 UI). The patient died of a non-related cause 3 months after diagnosis. A Burkitt's lymphoma included in the study showed multiple mutations in all regulatory regions. The Asn11 polymorphism was detected in one CLL and two follicular lymphomas. No 
Figure 3
Silver-stained SSCP analysis of several c-myc exon 2 regions in MCLs (a and b) and other NHLs (c and d) using two different electrophoretic SSCP conditions: 15% polyacrylamide gels (a and c) and 8% polyacrylamide gels containing 7% glycerol (b and d). In both conditions, one FCL and four MCL showed altered SSCP patterns compared to the wild-type (WT) pattern of a reactive tonsil. The SSCP altered patterns of MCL cases corresponded to a previously described polymorphism in Asn11. The Raji cell line was used as a positive control.
Figure 4
PCR-direct sequencing of the FCL case showing an altered SSCP pattern in Figure 3 . The c-myc gene alteration in this case was identified as a missense mutation in Pro59.
mutations in the exon 1 region examined were detected in any of the non-Burkitt's lymphomas.
Discussion
Transgenic animal experiments have shown the strong cooperative effect of c-myc and cyclin D1 in the development of B cell lymphomas. In this study we found c-myc mRNA overexpression in a subset of MCLs with a tendency to be more frequently expressed in blastoid than in typical variants. Similarly, c-myc overexpression was also present in other NHLs with a higher frequency in aggressive than indolent lymphomas. Interestingly, higher mRNA levels were more frequently found in transformed lymphomas from CLL or follicular lymphomas than in primary large cell lymphomas. How cmyc may participate in the pathogenesis of these tumors is not clear. In vitro studies suggest that c-myc may activate both cyclin D1-and cyclin E-associated kinases. Particularly, cmyc induction seems to activate cyclin E/CDK2 complexes probably by blocking the inhibitory effect of p27 KIP1 . 29 In addition, c-myc seems to induce the expression of the cdc25A and B phosphatases which remove inhibitory phosphates at Thr-14 and Tyr-15 of CDKs. 30 In spite of the involvement of c-myc in different steps of cell cycle regulation, in our study c-myc mRNA levels did not correlate with cell proliferation in MCLs. These findings are concordant with a previous study in which c-myc mRNA levels did not correlate with cell proliferation in other NHLs indicating the need for additional cooperative factors in the proliferative control of these tumors. 31 To determine whether the c-myc dysregulation in these tumors could be related to genetic alterations, we analyzed possible structural alterations of the gene and mutations in the regulatory regions of exon 1, intron 1 and exon 2. c-myc gene alterations were extremely rare in MCL because we only found a moderate amplification of the gene in one blastoid MCL, and no mutations in regulatory regions were detected in any case. These findings indicate that mRNA upregulation in MCLs is not associated with structural alterations of the gene or mutations in exon 1/intron 1/exon 2 regulatory regions.
In other nodal NHLs, gene amplifications or rearrangements were also rare because only the Burkitt's lymphoma included in the study showed a c-myc rearrangement. However, point mutations in exon 1/intron 1 region and exon 2 were more frequently found, particularly in aggressive variants. In these tumors, point mutations were detected in nine cases and, in five of them, we could rule out a polymorphism because the alteration was not present in DNA obtained from normal samples of the same patients. One of these mutated cases was the Burkitt's lymphoma with c-myc gene rearrangement. This tumor had multiple mutations in exon 1/intron 1 boundary and exon 2 as it has been previously described in these tumors and in other aggressive lymphoproliferative disorders with rearrangements of the gene. 13 The high number of mutations in tumors with c-myc rearrangements are considered to be an acquired phenomenon probably related to the hypermutation activity associated with the translocation of the immunoglobulin genes, and they may contribute to the oncogenic effect of the gene. 10 In other non-Hodgkin's lymphomas in our study only one nucleotide change was detected in each case and they were not associated with gene rearrangements. Similarly, mutations in regulatory regions independent of gene rearrangements have also been described in MALT lymphomas and in occasional anaplastic large cell lymphomas. 15, 17 Three of the eight point mutations detected in our tumors were localized in well-defined regulatory regions of the exon 1/intron 1 boundary or exon 2. One mutation in a Richter's syndrome was detected close to the exon 1 intron 1 boundary (position 2886, at 5 bases from the 5Ј end of intron 1). This region participates in the control of transcriptional elongation. Mutations in this area may remove the block to transcription elongation required to downregulate the expression of the gene. 32, 33 A second mutation in a primary large cell lymphoma was localized within the sequence of the MIF-1 box. Mutations in these sites may affect the binding of the c-myc intron factor which functions as a negative regulatory element of c-myc transcription. 11, 34 Finally, a large cell follicular lymphoma (grade 3) showed a point mutation in codon 59 of exon 2. Mutations in exon 2 occurring in different lymphomas frequently cluster between codons 56-71 and 114-129. 13, 14, 16 Interestingly, many of these mutations are located in phosphorylation sites (Thr58 and Ser62) or near flanking sequences, suggesting that the oncogenic properties of these mutations could be due to a block of regulatory phosphorylations. 35 Mutations in these sites seem to increase the c-myc transforming activity by rendering the protein more resistant to the suppressor effect of p107. 12 In addition to these three mutations, we also detected different point mutations in other areas of the intron 1 in five primary large cell lymphomas. At least three of these five mutations were not detected in the normal DNA of the patient, suggesting that they were acquired in the malignant transformation. However, the pathogenic significance of these mutations is not clear because they were found in intronic positions not characterized as regulatory regions of the gene. Furthermore, one of these changes corresponded to a case that could be studied for mRNA analysis and the c-myc expression levels were undetectable, suggesting that this mutation may not have an important role in the deregulation of the gene.
In the analysis of exon 2 we also detected the Asn 11 polymorphism in seven tumors, four MCL, two follicular lymphomas and one CLL. This change has been interpreted as a somatic gene mutation in different studies of lymphoproliferative disorders. 14, 16 However, it is now known that this is a polymorphic change with an estimated gene frequency of 6.5%. 28 c-myc gene alterations have been involved in the progression of a subset of follicular lymphomas and other indolent lymphoproliferative disorders. 36, 37 The point mutations in regulatory regions in our nodal NHL were all detected in primary or transformed large cell tumors and in one large cell follicular lymphoma. The only MCL with a c-myc gene amplification was a blastoid variant. However, gene alterations were remarkably low in MCL indicating that c-myc gene aberrations do not play a major role in the pathogenesis of these tumors. In vitro studies have shown that c-myc is downstream of the cyclin D1/CDK4 and p16
INK4a regulatory pathway. Moreover, the oncogenic potential of these genes requires an active c-myc to exert their transforming activity. 38 On the other hand, aggressive MCL show frequent inactivation of p16
INKa gene. 39, 40 These findings may allow speculation that MCL with oncogenic hits in, at least two upstream regulatory elements of the pathway, such as cyclin D1 and p16
INKa genes, do not exert any pressure to select additional alterations in downstream regulatory genes such as c-myc.
In conclusion, our findings indicate that c-myc is overexpressed in a subset of MCL and other NHLs with a higher incidence in aggressive than in indolent lymphomas. However, the c-myc upregulation in all these tumors does not correlate with the presence of structural alterations of the gene. Although genetic alterations were relatively uncommon in both groups of lymphomas, they were more frequently found in other types of NHLs than in mantle cell tumors.
